Wells Fargo Maintains Overweight on Iovance Biotherapeutics, Raises Price Target to $18

Wells Fargo analyst Yanan Zhu has maintained an Overweight rating on Iovance Biotherapeutics (NASDAQ: IOVA) and raised the price target from $14 to $18. This adjustment reflects a positive outlook on the company's performance.